Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

@inproceedings{Nitti2013MirabegronFT,
  title={Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies},
  author={Victor W. Nitti and Vik Khullar and Philip E. V. A. Van Kerrebroeck and Sender Herschorn and Javier Cambronero and Javier C Angulo and Mary Beth Blauwet and Caroline A Dorrepaal and Emad Siddiqui and Nancy E Martin},
  booktitle={International journal of clinical practice},
  year={2013}
}
INTRODUCTION To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. METHODS This prespecified pooled analysis of three randomised, double-blind, placebo-controlled, 12-week studies, evaluated efficacy and safety of once-daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS